MedTrace Logo

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

NCT03052842 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-22

Study results available
· View outcomes & findings →

Summary

Single-blind study to evaluate whether C16G2 Strip administered in multiple doses can effectively kill the bacteria in the oral cavity that cause dental caries..

Conditions

  • Dental Caries

Interventions

DRUG

C16G2 Strip

Antimicrobial Peptide

OTHER

Placebo Strip

Placebo

Sponsors & Collaborators

  • Vantage Data Designs, Inc.

    collaborator INDUSTRY

  • E Squared Trials and Registries, Inc.

    collaborator INDUSTRY

  • Agility Clinical, Inc.

    collaborator INDUSTRY

  • Armata Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Pittaway, DMD · Plaza West II Dental Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-09
Primary Completion
2017-04-05
Completion
2017-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052842 on ClinicalTrials.gov